Introduction {#Sec1}
============

Tuberculosis remains a global health problem, with an increasing number of new cases (10.4 million in 2015) and an increasing problem of drug resistance \[[@CR1]\]. New therapeutic agents which act against novel bacterial targets are needed to supplement and supplant the current drugs. Therefore there is great interest in finding new chemical matter that has activity against the causative agent, *Mycobacterium tuberculosis*. A large effort has been expended to examine small molecule libraries as starting point for drug discovery \[[@CR2], [@CR3]\]. Less attention has been paid to natural products as starting points for a discovery program. We were interested in expanding chemical diversity to identify novel inhibitors which could be used either as starting points for a drug discovery program or as probes to identify novel targets.

Main text {#Sec2}
=========

A phenotypic screen to identify compounds with activity against *M. tuberculosis* using the MSD collection of purified natural products was initiated. A small set (\~ 500) of natural products for activity against *M. tuberculosis* H37Rv-LP (ATCC 25618) expressing a red fluorescent protein were tested \[[@CR4]--[@CR6]\]. Compounds were tested at a single concentration of 20 µM. Growth was measured by fluorescence after 5 days of aerobic culture in Middlebrook 7H9 medium supplemented with 10% v/v OADC (oleic acid, albumin, [d]{.smallcaps}-glucose, catalase; Becton--Dickinson) and 0.05% w/v Tween 80 at 37 °C in 384-well plates. Growth inhibition was calculated with reference to controls (DMSO only). Within this screen, hits were defined as having \> 30% inhibition of growth. Hits were confirmed by testing compounds in a dose response, using two readouts for growth---OD~590~ and fluorescence (Ex 560/Em 590) \[[@CR4]--[@CR6]\]. Compounds were solubilized in DMSO, and a ten point, twofold serial dilution prepared in DMSO. *M. tuberculosis* was cultured in Middlebrook 7H9 supplemented with 10% v/v OADC and 0.05% w/v Tween 80. Cultures were inoculated at a final OD~590~ of 0.02 into 96-well plates containing compounds (final DMSO concentration of 2%). The starting concentration for compounds was 20 µM. Growth inhibition curves were plotted using the Levenberg--Marquardt algorithm and the concentration that resulted in 90% inhibition of growth was determined (MIC~90~). For active compounds, assays were conducted at least twice. Rifampicin was used as a control in each plate---for comparison the MIC of rifampicin was 0.0077 µM.

From these experiments, MSD-453 confirmed as a hit and further analogs based on similarity searches were ordered and tested. The initial hit, a cyclic hexapeptide, cyclo\[*N*-(Me)Phe-Pro-Phe-*N*-(OH)Leu-Piz-Piz\] (compound **1**) had good activity against *M. tuberculosis*, with an MIC~90~ of 2.3 µM (Table [1](#Tab1){ref-type="table"}). Several natural congeners (**2**--**4)** and semi-synthetic and synthetic analogs (**5**--**16)** were available from the MSD sample library and were tested for activity against replicating *M. tuberculosis* under aerobic conditions in liquid medium. Structural identities and purity of the compounds were verified prior to anti-tubercular testing. Four other analogs (**2**--**5**) exhibited intermediate inhibitory potencies (MIC~90~ of 2.8--8.9 μM), whereas eleven compounds (**6**--**16**) showed no inhibitory activity (MIC~90~ \> 20 µM).Table 1Activity of cyclic peptides against *M. tuberculosis*Compound numberStructureSynonymMIC~90~**1**![](13104_2018_3526_Figa_HTML.gif){#d29e548}MSD-0452.3 ± 0.5**2**![](13104_2018_3526_Figb_HTML.gif){#d29e567}MSD-5242.8 ± 0.8**3**![](13104_2018_3526_Figc_HTML.gif){#d29e586}MSD-0998.9 ± 1.8**4**![](13104_2018_3526_Figd_HTML.gif){#d29e605}MSD-1357.3 ± 1.9**5**![](13104_2018_3526_Fige_HTML.gif){#d29e624}MSD-29808.2 ± 1.2**6**![](13104_2018_3526_Figf_HTML.gif){#d29e643}MSD-695\> 20**7**![](13104_2018_3526_Figg_HTML.gif){#d29e662}MSD-408\> 20**8**![](13104_2018_3526_Figh_HTML.gif){#d29e681}MSD-196\> 20**9**![](13104_2018_3526_Figi_HTML.gif){#d29e700}MSD-818\> 20**10**![](13104_2018_3526_Figj_HTML.gif){#d29e719}MSD-109\> 20**11**![](13104_2018_3526_Figk_HTML.gif){#d29e738}MSD-810\> 20**12**![](13104_2018_3526_Figl_HTML.gif){#d29e758}MSD-008\> 20**13**![](13104_2018_3526_Figm_HTML.gif){#d29e777}MSD-369\> 20**14**![](13104_2018_3526_Fign_HTML.gif){#d29e796}MSD-229\> 20**15**![](13104_2018_3526_Figo_HTML.gif){#d29e815}MSD-049\> 20**16**![](13104_2018_3526_Figp_HTML.gif){#d29e834}MSD-064\> 20MIC~90~ were determined against aerobically-cultured *M. tuberculosis* in liquid culture after 5 days of growth \[[@CR5]\]. Growth inhibition curves were plotted using the Levenberg--Marquardt algorithm and the concentration that resulted in 90% inhibition of growth was determined (MIC~90~). MIC~90~ were determined a minimum of two times for active compounds. Data are average ± standard deviation

Although the dataset of compounds tested are limited, some elements of the structure--activity relationship (SAR) (Fig. [1](#Fig1){ref-type="fig"}) have been determined. Replacement of the *N*-hydroxyleucine with *N*-hydroxyisoleucine resulted in similar activity (**2**, MIC~90~ = 2.8 µM). Replacement of the phenylalanine with a valine reduced the activity slightly by three to fourfold (**3**, MIC~90~ = 8.9 µM). Similar reduced activity was seen after a double substitution of *N*-methylphenylalanine and phenylalanine with isoleucine and leucine (**4**, MIC~90~ = 7.3 µM). An *N*-alkyl-ketone in place of *N*-hydroxyleucine was tolerated, but reduced the biological activity by threefold (**5**, MIC~90~ = 8.2 µM), demonstrating that the *N*-hydroxyl group at that position is not critical. In contrast, the piperazic acids (Piz) were critical for activity of the molecule, since several tetrahydropiperazic (∆Piz) acid derivatives (**6**--**12**) and the pipecolic acid (Pip) (**13** and **15**) analog resulted in loss of anti-tubercular activity. *O*-Alkylation of the *N*-hydroxyleucine with an acetic acid or acetic acid ester abrogated activity (**13**--**14**). The combined replacement of *N*-methylphenylalanine with norvaline and phenylalanine with leucine also removed activity (**16**, MIC~90~ \> 20 μM). Based on these analogs, we were able to determine some limited structure--activity relationship (Fig. [1](#Fig1){ref-type="fig"}). Although the compounds were not as potent as rifampicin, they did have good activity, with a dynamic SAR ranging from low micromolar to inactive (\> 20 µM).Fig. 1*M. tuberculosis* cyclic hexapeptide structure-activity relationship. N--OH-Leu, *N*-hydroxyleucine; N--OH-Ile, *N*-hydroxyisoleucine; Phe, phenylalanine; Val, valine; N-Me-Phe, *N*-methylphenylalanine; Ile, isoleucine; Leu, leucine; Piz, piperazic acid; ∆Piz tetrahydropiperazic acid; Pip, pipecolic acid; N-Me-Nor Val, *N*-methyl-norvaline

The original hit molecule, MSD-453, along with several congeners \[[@CR7]--[@CR10]\] and synthetic analogs \[[@CR8]--[@CR12]\], were originally identified as sub-micromolar to low nanomolar oxytocin receptor antagonists. *M. tuberculosis* does not have a homolog of this receptor; thus, this series appears to have a different target in the pathogen.

In an attempt to identify the *M. tuberculosis* biochemical target, resistant mutants to two of the compounds were isolated. The potency of each compound on Middlebrook 7H10 medium containing 10% v/v OADC supplement was measured. MIC~99~ values were determined by the serial proportion method and defined as the minimum concentration required to prevent 99% growth on solid medium \[[@CR13]\]. Under these incubation conditions, the MIC~99~ was 1.6 and 0.8 µM for MSD-045 and MSD-099 respectively (Table [2](#Tab2){ref-type="table"}). Resistant mutants were isolated on Middlebrook 7H10 plus 10% v/v OADC at 5X MIC of each compound after 3--4 weeks growth \[[@CR14]\]. Colonies were tested for MIC~99~ on solid medium to confirm resistance (Table [2](#Tab2){ref-type="table"}). In this longer term assay on solid media both compounds showed better potency than when tested for shorter time (5 days) assay in liquid media (Table [1](#Tab1){ref-type="table"}). Although nine confirmed resistant isolates were subjected to whole genome sequencing \[[@CR15]\], no mutations were observed in 8 of the strains. Strain LP-0458686-RM1 had two mutations, one in *gap* (Rv1436) and one in Rv1543, but these were not observed in any of the other eight strains. Thus no genotypic explanation for the observed resistance was determined. In this case, the resistance phenotype could be due to epigenetic phenomena.Table 2*M. tuberculosis* strains resistant to hexapeptide inhibitor compoundsStrainCompoundMIC~99~ (µM)WTMSD-0451.6LP-0458690-RM1MSD-04513LP-0458690-RM2MSD-04525LP-0458690-RM3MSD-04525LP-0458690-RM4MSD-04525LP-0458690-RM5MSD-04525LP-0458690-RM6MSD-04525WTMSD-0990.8LP-0458686-RM1MSD-0993.1LP-0458686-RM2MSD-0993.1LP-0458686-RM3MSD-0993.1MIC~99~ were determined against *M. tuberculosis* resistant isolates on solid medium after 3--4 weeks. MIC~99~ was determined by the serial proportion method and defined as the minimum concentration required to prevent 99% growth \[[@CR13]\]

In conclusion, a series of cyclic natural product peptides with activity against *M. tuberculosis,* which could form the basis of further exploratory work including target identification, are disclosed. Future work to identify the intracellular target would assist in further development of this class of molecules.

Limitations {#Sec3}
===========

No in vivo activity is reported yet.The mode of resistance is not yet understood.The target for the series is not known.
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